Knowledge, attitudes, and practices regarding hantavirus disease and acceptance of a vaccine trial in rural communities of southern Chile

Gestores bibliográficos

item.contributor.advisor

ORCID:

Journal Title

Journal ISSN

Volume Title

Publisher

Taylor & Francis Online

item.page.isbn

item.page.issn

item.page.issne

item.page.doiurl

item.page.extent

8

item.page.accessRights

item.page.other

item.page.references

Abstract

Andes hantavirus cardiopulmonary syndrome, transmitted by Oligoryzomys longicaudatus, has no approved treatment, a case fatality rate of 35%, and documented person-to-person transmission. An Andes vac...

Description

item.page.coverage.spatial

item.page.sponsorship

Citation

Human Vaccines & Immunotherapeutics Volume 13, 2017, Issue 4, pages 808-815

item.page.dc.rights

item.page.dc.rights.url

Estadísticas de uso
1 0,8 0,5 0,3 0
Septiembre 2025Octubre 2025Noviembre 2025Diciembre 2025Enero 2026Febrero 2026Marzo 2026